Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
The news feed for Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) captures the company’s transition as it integrates Decoy Therapeutics and pivots toward a peptide-conjugate antiviral and oncology platform. Press releases and regulatory announcements describe how Salarius, historically a clinical-stage biopharmaceutical company with oncology assets, completed a strategic merger with Decoy and is preparing to operate under the Decoy Therapeutics name and the Nasdaq ticker symbol DCOY.
Readers following SLRX news can expect updates on corporate transformation, including the planned and then confirmed changes to the corporate name and trading symbol, as well as details of the merger structure, preferred stock issuance and leadership changes documented in company communications and SEC filings. The news flow also highlights capital markets activity, such as underwritten public offerings of common stock and warrants, at-the-market issuances and efforts to regain and maintain compliance with Nasdaq listing standards, including reverse stock splits and panel monitoring.
Sector-specific coverage focuses on drug development and platform progress. Company announcements describe the IMP3ACT peptide-conjugate platform, pan‑coronavirus and broad-acting antiviral programs, and a peptide drug conjugate targeting GI cancers. News items also cover collaborations, notably with Texas Biomedical Research Institute for in vitro testing of peptide conjugate fusion inhibitors across influenza strains including H5N1 avian flu, and recognition from programs such as the Massachusetts Life Sciences Seed Fund, the Google AI startup program, the NVIDIA Inception program and BARDA’s BLUE KNIGHT initiative.
By monitoring this page, investors and observers can review historical and ongoing disclosures around SLRX’s oncology heritage, its integration with Decoy’s AI- and ML-enabled peptide-conjugate platform, financing transactions and interactions with the Nasdaq Capital Market, all drawn from company-issued news and related filings.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced a partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to explore new indications and potential biomarkers for its lead drug candidate, seclidemstat. This oral inhibitor targets lysine-specific histone demethylase 1 (LSD1), a key enzyme in cancer progression. A Phase 1/2 trial is ongoing for sarcomas and now includes hematologic cancers. CEO David Arthur emphasized the collaboration as a validation of seclidemstat's potential and aims to provide new treatment options for patients with difficult-to-treat cancers.
Salarius Pharmaceuticals (Nasdaq: SLRX) has been included in the FTSE Global Micro Cap Index, effective September 20, 2021. This milestone is aimed at enhancing the company's visibility among institutional investors and increasing stock liquidity, as noted by CEO David Arthur. The FTSE Global Micro Cap Index comprises 8,832 companies with a net market capitalization of $1.89 trillion, with 47% of its constituents based in the U.S. and 17.65% from the healthcare sector. This inclusion signals a positive year for Salarius, aligned with its ongoing clinical programs.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Life Science Investor Forum on September 16, 2021. The presentation, accessible to registered attendees, will cover the company's recent advancements and the clinical progress of seclidemstat, an oral LSD1 inhibitor. This drug is under evaluation in a Phase 1/2 trial for Ewing sarcoma and other cancers. Participants can also follow up with a recorded version of the presentation on the company's website after the event.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation, accessible to registered attendees starting at 7 a.m. ET on September 13, will cover the company's business overview, recent achievements, and clinical milestones for seclidemstat, an LSD1 inhibitor in trials for Ewing sarcoma and hematologic cancers. Salarius will also engage in one-on-one meetings with investors and pharmaceutical executives.
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) has announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational Conference on August 17, 2021, at 11 a.m. ET. The presentation will cover the company's business highlights, recent achievements, and future clinical milestones for seclidemstat, an oral LSD1 inhibitor. Salarius is advancing a Phase 1/2 clinical trial for Ewing sarcoma and other cancers. Interested participants can register for the event at no cost, with a recording available post-event on Salarius' website.
Salarius Pharmaceuticals (Nasdaq: SLRX) recently reported significant developments during Q2 2021, including the commencement of clinical trials for its lead drug candidate, seclidemstat, in various cancer types. The company has cash reserves of $33.1 million, enough to fund ongoing clinical programs. Initial findings presented at ASCO 2021 indicated preliminary efficacy for seclidemstat, with a manageable safety profile. A Phase 1/2 trial is underway for treating hematologic cancers in collaboration with MD Anderson Cancer Center, while multiple new sites and patient groups are being added for sarcoma studies.
Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and live audio webcast on August 5, 2021, at 10:00 a.m. ET to discuss its second quarter and year-to-date 2021 financial results. The conference call can be accessed via phone or through the company’s website. Salarius is focused on developing cancer therapies, particularly its lead candidate, seclidemstat, which is in a Phase 1/2 clinical trial for various sarcomas, including Ewing sarcoma. The company has received several designations from the U.S. FDA to support its work.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that Dr. Aundrietta Duncan will present on seclidemstat at the Epigenetic Therapeutic Targets Summit on July 14, 2021. Her talk, titled 'Targeting FET-Rearranged Sarcomas Through Inhibition of LSD1', will explore the potential of LSD1 inhibition in treating Ewing-related sarcomas. Currently, seclidemstat is in a Phase 1/2 study for Ewing sarcoma and other related cancers, and has received multiple FDA designations. The presentation will be accessible to registered participants and later available on Salarius' website.
Salarius Pharmaceuticals (Nasdaq: SLRX) has expanded its ongoing clinical trial for seclidemstat to nine trial sites, including Fox Chase Cancer Center. The trial focuses on patients with relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas. Patient recruitment is underway, targeting safety and efficacy with three distinct patient arms. Seclidemstat, designed to inhibit the LSD1 enzyme, has shown promise in combination therapies, especially with topotecan and cyclophosphamide. Results are anticipated in 2022.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 3 p.m. ET. The presentation will cover the company's advancements in cancer therapies, with a focus on seclidemstat, currently in Phase 1/2 trials for Ewing sarcoma and hematologic cancers. Seclidemstat has received multiple designations from the FDA, demonstrating its potential in treating pediatric and other cancers. A recording of the presentation will be available post-event.